Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 350
- Registration Number
- NCT06588855
- Locations
- 🇺🇸
Digestive and Liver Center of Florida, Orlando, Florida, United States
🇺🇸Delta Gastroenterology & Endoscopy Center, Southaven, Mississippi, United States
🇺🇸Amel Med LLC, Georgetown, Texas, United States
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 180
- Registration Number
- NCT06537310
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
🇩🇰Rigshospitalet; Fase 1 Enhed - Onkologi, København Ø, Denmark
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 362
- Registration Number
- NCT06534983
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇩🇪Uniklinikum Heidelberg, Heidelberg, Germany
🇮🇹IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT06503250
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
🇨🇳Tianjin First Central Hospital, Tianjin, China
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06497556
- Locations
- 🇺🇸
Banner Health MD Anderson AZ, Gilbert, Arizona, United States
🇺🇸Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06496568
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06450639
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny w Poznaniu; Od. Kliniczny Neurologii Dzieci i Młodzieży, Poznań, Poland
🇵🇱Instytut Centrum Zdrowia Matki Polki; Klinika Neurologii Rozwojowej i Epileptologii, Łódź, Poland
🇺🇸Child(ren's) Hosp(ital) of the king's daughters, Norfolk, Virginia, United States
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT06439576
- Locations
- 🇨🇳
Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China
🇨🇳Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology; Opthamology, Wuhan, China
🇨🇳Hebei Eye Hospital, Xingtai, China
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 245
- Registration Number
- NCT06402838
- Locations
- 🇫🇷
Hôpital de la Timone; Neurologie, Marseille Cedex 5, France
🇨🇱Centro de Investigación Clínica UC-CICUC, Santiago, Chile
🇨🇱Hospital Clinico Univ de Chile, Santiago, Chile
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 348
- Registration Number
- NCT06369220
- Locations
- 🇺🇸
San Francisco City Clinic, San Francisco, California, United States
🇺🇸Planned Parenthood of Northern, Central, and Southern New Jersey, Inc., Hamilton Square, New Jersey, United States
🇺🇸Planned Parenthood of Northern, Central and Southern New Jersey, Perth Amboy, New Jersey, United States